{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=39&state=Colorado", "query": { "state": "Colorado", "city": "Denver", "page": 39 }, "page_size": 10 }, "pagination": { "page": 39, "page_size": 10, "total_count": 7455, "total_pages": 746, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=40&state=Colorado&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=38&state=Colorado&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T02:13:02.958Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01376557", "title": "Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "75 mg LX4211", "type": "DRUG" }, { "name": "200 mg LX4211", "type": "DRUG" }, { "name": "400 mg LX4211", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lexicon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 299, "start_date": "2011-06", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2014-10-31", "last_synced_at": "2026-11-05T02:13:02.958Z", "location_count": 56, "location_summary": "Anaheim, California • Carmichael, California • Greenbrae, California + 48 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Carmichael", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01376557" }, { "nct_id": "NCT00487565", "title": "Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Osteoarthritis", "Rheumatoid Arthritis", "Post-traumatic Arthritis", "Juvenile Arthritis" ], "interventions": [ { "name": "Total knee arthroplasty", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "DePuy Orthopaedics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 210, "start_date": "2006-09", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2013-08-14", "last_synced_at": "2026-11-05T02:13:02.958Z", "location_count": 3, "location_summary": "Denver, Colorado • Pittsburgh, Pennsylvania • Virginia Beach, Virginia", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Virginia Beach", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00487565" }, { "nct_id": "NCT01668667", "title": "Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Restless Legs Syndrome" ], "interventions": [ { "name": "GSK1838262 600 mg", "type": "DRUG" }, { "name": "GSK1838262 450 mg", "type": "DRUG" }, { "name": "GSK1838262 300 mg", "type": "DRUG" }, { "name": "GSK1838262 Placebo match", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "XenoPort, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 501, "start_date": "2012-06", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2021-05-24", "last_synced_at": "2026-11-05T02:13:02.958Z", "location_count": 42, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01668667" }, { "nct_id": "NCT07221500", "title": "A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)" ], "interventions": [ { "name": "NX-5948", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-10-15", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-05T02:13:02.958Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Duarte, California • Los Angeles, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07221500" }, { "nct_id": "NCT01806545", "title": "An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arteriovenous Fistula" ], "interventions": [ { "name": "SRM003", "type": "BIOLOGICAL" }, { "name": "Participating Site's standard practice", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2013-03-26", "completion_date": "2014-10-27", "has_results": true, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-11-05T02:13:02.958Z", "location_count": 47, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fresno, California + 41 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01806545" }, { "nct_id": "NCT07136012", "title": "OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiovascular Disease" ], "interventions": [ { "name": "Olpasiran", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "105 Years", "sex": "ALL", "summary": "50 Years to 105 Years" }, "enrollment_count": 11000, "start_date": "2025-08-22", "completion_date": "2031-10-20", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-11-05T02:13:02.958Z", "location_count": 205, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 170 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07136012" }, { "nct_id": "NCT03180853", "title": "Multiple Myeloma Patient Registry", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [], "intervention_types": [], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2017-05-08", "completion_date": "2018-04-06", "has_results": false, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-11-05T02:13:02.958Z", "location_count": 69, "location_summary": "Phoenix, Arizona • Fort Smith, Arkansas • Hot Springs, Arkansas + 63 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03180853" }, { "nct_id": "NCT00000737", "title": "A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cachexia", "HIV Infections", "HIV Wasting Syndrome" ], "interventions": [ { "name": "Dronabinol", "type": "DRUG" }, { "name": "Megestrol acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2008-08-25", "last_synced_at": "2026-11-05T02:13:02.958Z", "location_count": 9, "location_summary": "Denver, Colorado • Chicago, Illinois • Wichita, Kansas + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Wichita", "state": "Kansas" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000737" }, { "nct_id": "NCT03434028", "title": "Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Septic Shock" ], "interventions": [ { "name": "Early Vasopressors", "type": "DRUG" }, { "name": "Early Fluids", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1563, "start_date": "2018-03-07", "completion_date": "2022-08-24", "has_results": true, "last_update_posted_date": "2023-07-06", "last_synced_at": "2026-11-05T02:13:02.958Z", "location_count": 50, "location_summary": "Tucson, Arizona • Fresno, California • Los Angeles, California + 36 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434028" }, { "nct_id": "NCT03617536", "title": "A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Diseases", "Pruritus" ], "interventions": [ { "name": "CR845 0.25 mg Oral Tablet", "type": "DRUG" }, { "name": "CR845 0.5 mg Oral Tablet", "type": "DRUG" }, { "name": "CR845 1 mg Oral Tablet", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cara Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 269, "start_date": "2018-07-05", "completion_date": "2019-11-14", "has_results": true, "last_update_posted_date": "2024-01-24", "last_synced_at": "2026-11-05T02:13:02.958Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Florence, Alabama • Phoenix, Arizona + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Florence", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Prescott", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03617536" } ] }